Kapağı yeniden konumlandırmak için sürükleyin
Aşağıdaki
Yaklaşık
Alzheimer’s disease (AD) remains one of the most capital-intensive and failure-prone areas in biopharma. Decades of high-profile setbacks created what many termed the Alzheimer’s graveyard. Yet recent approvals targeting amyloid biology have demonstrated a critical shift: regulatory pathways are viable—but only when programs are designed with precision and foresight.
Aşağıdaki
(19)
İzleyiciler
(1)
Avatarını kırp
